Pacific Biosciences of California, Inc. (PACB) is a Medical - Devices company in the Healthcare sector, currently trading at $1.57. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is PACB = $3 (+74.6% upside).
Valuation: PACB trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.1.
Financials: revenue is $160M, +12.3%/yr average growth. Net income is $546M (loss), growing at -25%/yr. Net profit margin is -341.5% (negative). Gross margin is 31.7% (-6.5 pp trend).
Balance sheet: total debt is $759M against $5M equity (Debt-to-Equity (D/E) ratio 141.98, leveraged). Current ratio is 6.89 (strong liquidity). Debt-to-assets is 96.9%. Total assets: $784M.
Analyst outlook: 9 / 18 analysts rate PACB as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 29/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
